GlobeNewswire·Nov 5, 2026, 4:05 PM ET

Quantum-Si Reports Third Quarter 2026 Financial Results and Provides Business Update

QSI

Quantum-Si reported Q3 2026 revenue of $212,000, a decrease from $552,000 in Q3 2025, during the transition from Platinum to Proteus platforms.
The company highlighted interim Proteus data showing approximately 30 times more sequencing output per chamber in controlled peptide studies.
Proteus technology successfully detected 19 of 20 amino acids, with the 20th expected before year-end.
Quantum-Si launched a pre-order program for the Proteus platform to secure customer priority access ahead of the anticipated commercial launch in Q2 2027.
Full-year 2026 financial guidance was updated to lower adjusted total operating expenses to $87.0 million or less and total cash usage to $87.0 million or less.
Total operating expenses for Q3 2026 were $23.9 million, down from $40.0 million in the prior-year period, primarily due to the absence of lease termination and legal settlement expenses.
A reduction in force affecting approximately 20% of headcount was completed in Q3 2026, expected to generate $12 million in annual operating expense savings.
The company reported a net loss of $22.3 million for Q3 2026, compared to $35.7 million in the same period last year.
Cash, cash equivalents, and marketable securities totaled $149.4 million as of September 30, 2026, providing a runway into the fourth quarter of 2028.
CEO Jeff Hawkins stated that instrument variability issues have been substantially addressed and that design activities for additional instrument cycles are complete.
Supply chain constraints related to AI-driven demand have led to earlier component orders and safety stock building, though these are not expected to delay the Q2 2027 launch.

Company: Quantum-Si Incorporated
Keywords: Nasdaq:QSI, Quantum-Si Incorporated